Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links

Pozen gets patent on pain management product



18th August,2005: The United States Patent and Trademark Office has issued to Pozen U.S. patent number 6,926,907 'Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs'. This patent includes claims to pharmaceutical compositions that may contain a non-steroidal anti-inflammatory drug (NSAID) and an acid inhibitor, e.g., a proton pump inhibitor (PPI). Pozen’s PN (PPI/NSAID) combination drug candidates are covered under this patent, a company release said.

In the wake of cardiovascular safety concerns regarding the COX-2 selective NSAIDs, physicians are now recommending use of traditional non-selective NSAIDs with acid-suppressive co-therapy to prevent gastrointestinal complications. POZEN's PN drug candidates are being designed to provide this type of therapy with the added benefit of ensuring adherence with the use of the gastroprotective PPI with every dose of NSAID.

The Pozen PN tablet is designed to initially release the PPI component in the stomach and the NSAID component is released only in a lower acid environment. Pozen completed a 14-day proof-of-concept study with its drug candidate PN 100 which demonstrated that PN 100 was highly effective in preventing gastric mucosal injury compared with an NSAID alone. The results of this study have been selected for platform presentation at the Annual Scientific Meeting of the American College of Gastroenterology in November.

The PN drug candidates are being developed for the management of pain and inflammation associated with conditions such as osteoarthritis, which affects more than 20 million people in the United States, the Pozen release said.

Pozen is a pharmaceutical company developing therapeutic advancements for diseases with unmet medical needs where it can improve efficacy, safety, and/or patient convenience. Pozen has focused its efforts primarily on the development of pharmaceutical products for the treatment of migraine. The company is also exploring the development of product candidates in other pain-related therapeutic areas. Pozen has development and commercialization alliances with GlaxoSmithKline, Valeant Pharmaceuticals North America, a subsidiary of Valeant Pharmaceuticals International (formerly Xcel Pharmaceuticals, Inc.), and Nycomed Danmark ApS. The company's common stock is traded on The Nasdaq Stock Market under the symbol "POZN".


Pharma News Headlines

Cancer News

Cardiac News


Pharma industry news


Heart disease deaths more among New Yorkers

Pfizer to offer drugs risk/benefit summary to consumers 

Merck lied to public on Vioxx: lawyer tells jurors

Novartis acquires rights of kidney dialysis drug from SeBo

J&J's Concerta approved treatment of ADHD in teenagers in Canada

US FDA stalls Roche’ Accutane use in pregnancy

Novo Nordisk, Eli Lilly remove insulin products from Australia

British drug supply chain safety questioned after another fake Lipitor find

Wyeth starts support programme for Effexor patients

P&G’s Actonel with Calcium approved for osteoporosis

Pozen gets patent on pain management product

Genmab studies new drug for rheumatoid arthritis

Painkillers may increase blood pressure: study

Nektar buys out Aerogen for $32 m

Predix records positive data on anxiety drug

Insmed files against Increlex approval

Hepatitis A vaccine for kids approved in US

Psoriasis drug data positive: Cytochroma

Novo Nordisk’s 24-hour acting insulin Levemir gets US FDA okay

US FDA approves Teva's generic for osteoporosis 

Pfizer files NDA for Sutent in US

BioVeris licenses Baxter's vaccine portfolio

TheraQuest receives 2nd Orphan Drug status for neuralgia drug

Real-time glucose monitoring device approved in US

Halozyme gets FDA nod for bladder cancer therapy

Migenix to commence phase 2b studies in hep C therapy

Barr gets US FDA okay for clonazepam tabs

Anorexia drug study results positive: Par

GlaxoSmithKline begins phase III trials of new HIV drug

Ranbaxy's 7 anti retrovirals included in WHO list

FDA tightens restrictions on acne drug

Voglibose tabs launched in Japan

Remicade researcher gifts $ 105m to NYU

Par loses ondansetron case to GSK

Mistral starts clinical studies for generic

Carl Icahn sells Mylan shares

Florida sues Mylan, Teva and Watson

Dey and Connecticut settle pricing dispute

Germany set to stop rabies crossing borders

Office to review DTC drug advertisements in US

British docs to be trained in communication, safety

FDA okays acrylic lens for cataract patients 

Corautus to go ahead with angina drug studies 

Americans turn the low-fat way

Chemicals in plastics pose danger

US committee probes doctors’ complicity with Wall Street analysts

Meda buys out rival Viatris

US FDA nod for new levofloxacin regimen to treat acute bacterial sinusitis

Pozen files for new migraine treatment

New therapy for pancreatic cancer under review

New device inducing blood flow to heart granted US patent

NIH announces grants for faster, cheaper DNA sequencing

DOV starts phase III trial of pain drug in US

Alcohol linked cancers: Acetaldehyde in spot light

Hypertension `just above normal’ too risky

Gene causes infertility drugs go awry: study

China’s pig flu outbreak

Cardiac Science-Defibtech lawsuit settled

Peregrine starts Phase-1 anti-viral trial of Tarvacin

Dr. Reddy's launches immune booster for children

Lupin in pact with Kyowa of Japan

Bird flu vaccine may work in humans: US researchers



Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links

Latest updates    Contact Us - Feedback    About Us